Search details
1.
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.
Ann Oncol
; 33(1): 42-56, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34653632
2.
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
Ann Oncol
; 32(5): 661-672, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33736924
3.
Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.
Ann Oncol
; 33(11): 1204-1206, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35926816
4.
Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.
Ann Oncol
; 32(9): 1194-1197, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34166757
Results
1 -
4
de 4
1
Next >
>>